ID

34346

Beschreibung

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

Link

https://clinicaltrials.gov/show/NCT01933516

Stichworte

  1. 16.01.19 16.01.19 -
  2. 26.04.20 26.04.20 -
  3. 01.05.20 01.05.20 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

16. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
Beschreibung

ID.1

Datentyp

boolean

patient with at least one measurable lesion.
Beschreibung

ID.2

Datentyp

boolean

patient with ecog performance status 0 or 1.
Beschreibung

ID.3

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
Beschreibung

ID.4

Datentyp

boolean

patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
Beschreibung

ID.5

Datentyp

boolean

patient who has mab therapy other than rituximab as prior line of therapy.
Beschreibung

ID.6

Datentyp

boolean

patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
Beschreibung

ID.7

Datentyp

boolean

patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
Beschreibung

ID.8

Datentyp

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
ID.2
Item
patient with at least one measurable lesion.
boolean
ID.3
Item
patient with ecog performance status 0 or 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
ID.5
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
ID.6
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
ID.7
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
ID.8
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video